{
    "topic_id": "AEFF232E-6F13-4E40-BB78-6E4A1751D8CC",
    "topic_name": "Neonatal Abstinence Syndrome",
    "supertopic": "Neonatology",
    "assembled_utc": "2025-07-26T14:47:47",
    "subtopics": [
        {
            "subtopic_id": "74624D93-5671-495D-A86F-46177070ACCF",
            "subtopic_title": "Definition and overview of Neonatal Abstinence Syndrome (NAS)",
            "sequence_no": 1,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a clinical condition characterized by withdrawal symptoms in newborns due to in utero exposure to substances, most commonly opioids. The abrupt discontinuation of these substances at birth triggers a spectrum of symptoms affecting multiple systems, including the central nervous system, gastrointestinal tract, and autonomic regulation. Clinically, infants with NAS often present with central nervous system hyperirritability, manifesting as excessive crying, tremors, and sleep disturbances, alongside autonomic signs such as temperature instability, sweating, and nasal congestion. Gastrointestinal symptoms, including poor feeding, vomiting, and diarrhea, further complicate the clinical picture. Diagnosis is primarily clinical, supported by maternal history and toxicology screening. Early identification is crucial to initiate appropriate management, which may involve pharmacological treatment with agents like morphine or methadone and non-pharmacological strategies, such as swaddling, minimal stimulation, and breastfeeding when appropriate. \n\nA key guideline in managing NAS is the use of standardized scoring systems, such as the Finnegan Neonatal Abstinence Scoring Tool, to assess symptom severity and guide treatment decisions. However, one common pitfall in clinical practice is under-recognition of non-opioid substance withdrawal, such as from benzodiazepines or alcohol, which can present with overlapping but distinct features. This oversight may delay appropriate interventions, exacerbating neonatal distress and prolonging hospital stays. Pediatricians must adopt a multidisciplinary approach, integrating obstetric, psychiatric, and social support services to address the complex needs of both the infant and the mother, ensuring optimal outcomes for the dyad.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                    "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                    "excerpt": "INTRODUCTION Premature birth is a leading cause of neonatal morbidity and mortality in India, accounting for about 35% of all neonatal deaths. India carries a huge burden of preterm births, with an estimated 7.5 million low-birth-weight infants born annually, of whom roughly 40% are preterm (over 3 million, nearly a quarter of the global preterm births). Preterm infants are classified by [...]"
                },
                {
                    "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                    "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                    "excerpt": "DEFINITION-OVERVIEW Typhoid fever, also known as enteric fever, is an acute systemic illness caused by Salmonella enterica serovar Typhi (Salmonella Typhi). The term \"enteric fever\" encompasses both typhoid fever (caused by S. Typhi) and the similar syndrome of paratyphoid fever (caused by Salmonella Paratyphi A, B, or C). These bacteria are highly adapted human-specific pathogens that [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "33A9D6C0-9FB4-407C-A5CB-2820472366CC",
                    "stem": "What causes Neonatal Abstinence Syndrome primarily?",
                    "explanation": "The primary cause of Neonatal Abstinence Syndrome is 'maternal substance use in pregnancy,' which exposes the fetus to substances that lead to withdrawal symptoms after birth.",
                    "correct_choice": "Maternal substance use in pregnancy",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Maternal substance use in pregnancy"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Premature birth complications"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Maternal malnutrition during gestation"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Congenital genetic mutations"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which is the main cause of NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "NAS is primarily caused by what?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                            "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                            "excerpt": "INTRODUCTION Premature birth is a leading cause of neonatal morbidity and mortality in India, accounting for about 35% of all neonatal deaths. India carries a huge burden of preterm births, with an estimated 7.5 million low-birth-weight infants born annually, of whom roughly 40% are preterm (over 3 million, nearly a quarter of the global preterm births). Preterm infants are classified by [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                            "excerpt": "DEFINITION-OVERVIEW Typhoid fever, also known as enteric fever, is an acute systemic illness caused by Salmonella enterica serovar Typhi (Salmonella Typhi). The term \"enteric fever\" encompasses both typhoid fever (caused by S. Typhi) and the similar syndrome of paratyphoid fever (caused by Salmonella Paratyphi A, B, or C). These bacteria are highly adapted human-specific pathogens that [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "9539F9D8-7156-4B58-AB47-86080EAE02DB",
                    "stem": "What is Neonatal Abstinence Syndrome (NAS)?",
                    "explanation": "Neonatal Abstinence Syndrome (NAS) is defined as 'withdrawal in newborns from substances' due to maternal substance use during pregnancy.",
                    "correct_choice": "Withdrawal in newborns from substances",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Withdrawal in newborns from substances"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Congenital heart defect in neonates"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Delayed growth due to malnutrition"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Infection passed during delivery"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Neonatal Abstinence Syndrome refers to what condition?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which condition describes NAS in neonates?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                            "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                            "excerpt": "INTRODUCTION Premature birth is a leading cause of neonatal morbidity and mortality in India, accounting for about 35% of all neonatal deaths. India carries a huge burden of preterm births, with an estimated 7.5 million low-birth-weight infants born annually, of whom roughly 40% are preterm (over 3 million, nearly a quarter of the global preterm births). Preterm infants are classified by [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                            "excerpt": "DEFINITION-OVERVIEW Typhoid fever, also known as enteric fever, is an acute systemic illness caused by Salmonella enterica serovar Typhi (Salmonella Typhi). The term \"enteric fever\" encompasses both typhoid fever (caused by S. Typhi) and the similar syndrome of paratyphoid fever (caused by Salmonella Paratyphi A, B, or C). These bacteria are highly adapted human-specific pathogens that [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "FBDF9B14-06FB-476F-B419-CBA8CFEF16E9",
                    "stem": "Which symptom is common in Neonatal Abstinence Syndrome?",
                    "explanation": "A common symptom of Neonatal Abstinence Syndrome is 'irritability and high-pitched crying,' which results from withdrawal in affected newborns.",
                    "correct_choice": "Irritability and high-pitched crying",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Irritability and high-pitched crying"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Cyanosis and heart murmurs"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Delayed tooth eruption"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Increased head circumference"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is a typical symptom of NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which feature is seen in NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                            "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_0",
                            "excerpt": "INTRODUCTION Premature birth is a leading cause of neonatal morbidity and mortality in India, accounting for about 35% of all neonatal deaths. India carries a huge burden of preterm births, with an estimated 7.5 million low-birth-weight infants born annually, of whom roughly 40% are preterm (over 3 million, nearly a quarter of the global preterm births). Preterm infants are classified by [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_0",
                            "excerpt": "DEFINITION-OVERVIEW Typhoid fever, also known as enteric fever, is an acute systemic illness caused by Salmonella enterica serovar Typhi (Salmonella Typhi). The term \"enteric fever\" encompasses both typhoid fever (caused by S. Typhi) and the similar syndrome of paratyphoid fever (caused by Salmonella Paratyphi A, B, or C). These bacteria are highly adapted human-specific pathogens that [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "48FCBC1E-7AC6-417B-A03F-3234682BC956",
            "subtopic_title": "Causes of NAS (maternal substance use during pregnancy)",
            "sequence_no": 2,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a complex condition resulting from the abrupt cessation of fetal exposure to substances, most commonly opioids, used by the mother during pregnancy. The primary cause is maternal substance use, which crosses the placenta and affects fetal neurodevelopment. Newborns with NAS often present with central nervous system hyperirritability, autonomic dysregulation, and gastrointestinal disturbances. International guidelines, such as those from the American Academy of Pediatrics (AAP), emphasize a multidisciplinary approach to managing NAS, including pharmacological treatment, non-pharmacological interventions, and maternal support. Maternal counseling is critical, as addressing underlying substance use disorders and providing psychosocial support can improve outcomes for both the infant and the mother. In the Indian context, challenges such as limited access to specialized care and stigma surrounding maternal substance use may complicate adherence to these guidelines. A common pitfall in managing NAS is focusing solely on the newborn while neglecting maternal care, which is integral to breaking the cycle of substance use and improving long-term outcomes. Effective management requires collaboration across pediatrics, obstetrics, psychiatry, and social services to ensure comprehensive care. Post-graduate trainees should recognize that while pharmacological interventions are essential for managing withdrawal symptoms, non-pharmacological strategies like rooming-in, breastfeeding (if safe), and skin-to-skin contact can significantly reduce symptom severity and hospital stays. Understanding the interplay between maternal health and neonatal outcomes is key to providing holistic care in cases of NAS.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "D9815F60-F5C5-46F2-8CC0-5841C91B900B",
                    "stem": "Which substance is most commonly associated with Neonatal Abstinence Syndrome?",
                    "explanation": "Opioids are the most commonly associated substances with Neonatal Abstinence Syndrome due to their ability to cross the placenta and cause withdrawal symptoms in the neonate.",
                    "correct_choice": "Opioids",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Opioids"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Alcohol"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Caffeine"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Tobacco"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the primary cause of Neonatal Abstinence Syndrome?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Neonatal Abstinence Syndrome is most linked to which substance?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "326CC048-526F-4696-84B8-F1B07C7F2CC7",
                    "stem": "Which maternal substance use can lead to Neonatal Abstinence Syndrome?",
                    "explanation": "Opioids are the primary substances responsible for Neonatal Abstinence Syndrome, as they can cause dependency and withdrawal symptoms in the neonate.",
                    "correct_choice": "Opioids",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Opioids"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Alcohol"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Caffeine"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Tobacco"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What maternal drug use causes Neonatal Abstinence Syndrome?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Neonatal Abstinence Syndrome is caused by maternal use of what?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "5590AF1D-F6C8-49DF-BB49-EE611AD06BB1",
            "subtopic_title": "Common substances associated with NAS (e.g., opioids, benzodiazepines, antidepressants)",
            "sequence_no": 3,
            "concept": "Neonatal Abstinence Syndrome (NAS) encompasses a range of withdrawal symptoms experienced by newborns following in utero exposure to substances, most commonly opioids, but also benzodiazepines, antidepressants, and other psychoactive drugs. Opioids, such as heroin, methadone, and prescription pain relievers, are the primary culprits, with approximately 50-80% of affected infants requiring pharmacological management despite optimal supportive care. Benzodiazepines and antidepressants are less frequently associated with NAS but can contribute to prolonged withdrawal symptoms and complicate management. Clinically, opioid-induced NAS typically presents with central nervous system hyperirritability, autonomic dysregulation (e.g., temperature instability, sweating), and gastrointestinal disturbances, often necessitating a tailored approach to care. Effective management requires not only addressing the infant’s withdrawal symptoms but also supporting the mother or primary caregiver through counseling and social interventions, as maternal health and stability are critical to the infant’s recovery. Discharge planning must be meticulous, with coordinated follow-up to monitor developmental outcomes and prevent relapse or neglect in high-risk environments. A common pitfall in managing NAS is underestimating the importance of maternal engagement; failing to involve the mother in care planning can inadvertently exacerbate the infant's condition and hinder long-term recovery. Post-graduates must prioritize a holistic approach that integrates medical, social, and psychological support to optimize outcomes for both the infant and the family.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "02143630-A714-4335-AEF5-871114FC89A6",
                    "stem": "Which drug class is less commonly linked to NAS than opioids?",
                    "explanation": "Benzodiazepines are less commonly linked to Neonatal Abstinence Syndrome than opioids, though they can still cause withdrawal symptoms in neonates.",
                    "correct_choice": "Benzodiazepines",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Benzodiazepines"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Opioids"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Antidepressants"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Alcohol"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Compared to opioids, which drug is less frequent in NAS cases?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which substance is a secondary cause of NAS after opioids?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "14FC06AB-C8DF-494D-AF1B-B8F17049C904",
                    "stem": "Which substance is least likely to cause NAS?",
                    "explanation": "Antidepressants are least likely to cause Neonatal Abstinence Syndrome compared to other substances listed, though some cases have been reported.",
                    "correct_choice": "Antidepressants",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Alcohol"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Opioids"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Benzodiazepines"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Antidepressants"
                        }
                    ],
                    "correct_choice_index": 3,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which substance rarely contributes to Neonatal Abstinence Syndrome?",
                            "correct_choice_index": 3
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which of these drugs is least associated with NAS?",
                            "correct_choice_index": 3
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "32E7B23B-26AF-46FA-88C4-CC4481A98EE3",
                    "stem": "Which substance is most commonly associated with Neonatal Abstinence Syndrome?",
                    "explanation": "Opioids are the most commonly associated substance with Neonatal Abstinence Syndrome due to their high potential for dependence and withdrawal symptoms in neonates.",
                    "correct_choice": "Opioids",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Opioids"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Benzodiazepines"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Antidepressants"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Alcohol"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the primary cause of Neonatal Abstinence Syndrome?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Neonatal Abstinence Syndrome is most linked to which drug class?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "981A2C41-6935-4E79-A86C-59E908A83FF4",
            "subtopic_title": "Pathophysiology of NAS",
            "sequence_no": 4,
            "concept": "Neonatal Abstinence Syndrome (NAS) arises due to the abrupt cessation of in utero exposure to substances, most commonly opioids, leading to a spectrum of withdrawal symptoms in the newborn. The pathophysiology of NAS is rooted in the disruption of the fetal neurochemical environment. Chronic maternal opioid use leads to the accumulation of these substances in the fetal circulation, where they bind to opioid receptors, particularly in the central nervous system (CNS). These receptors, which modulate pain, arousal, and autonomic regulation, become dysregulated when the exogenous opioid supply is suddenly halted after birth. This results in CNS hyperirritability, manifesting as tremors, irritability, and high-pitched crying, as well as autonomic dysfunction, including temperature instability, sweating, and tachypnea. Gastrointestinal symptoms such as poor feeding and diarrhea are also common, further complicating neonatal care. A key management guideline is the use of validated scoring systems, such as the Finnegan Neonatal Abstinence Scoring Tool, to assess symptom severity and guide treatment, which may include pharmacological interventions like morphine or methadone for severe cases. A common pitfall in managing NAS is the premature weaning of pharmacological therapy, which can exacerbate withdrawal symptoms and prolong hospitalization. Optimal care requires a multidisciplinary approach, incorporating non-pharmacological strategies such as rooming-in, skin-to-skin contact, and breastfeeding when appropriate. Recognizing the interplay between neurochemical disruption and clinical presentation is essential for tailoring individualized care and improving outcomes in affected neonates.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                    "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                    "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-SYSTEMIC SPREAD S. Typhi survives in modified phagosomes, avoiding oxidative killing <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line499 to line507>. Macrophages transport the bacteria to lymph nodes, then the bloodstream, causing early bacteremia <Gupta, V. et al. (2021). Standard Treatment Guidelines: [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                    "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                    "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-ENTRY AND INVASION Infection starts via ingestion of contaminated food or water. Typically, 10^5 to 10^6 organisms are required, though food may buffer gastric acid and lower this threshold <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line485 to line493>. In the small intestine, the bacteria target M cells [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "2131ED78-A3DB-4D47-B6D9-94B6BE7304E1",
                    "stem": "Why do NAS infants exhibit hypertonia and tremors?",
                    "explanation": "Excess norepinephrine leads to hypertonia and tremors in NAS infants.",
                    "correct_choice": "Excess norepinephrine",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Excess norepinephrine"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Low dopamine levels"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Serotonin deficiency"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Acetylcholine excess"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What explains hypertonia in NAS infants?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Hypertonia and tremors in NAS are due to what?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                            "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                            "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-SYSTEMIC SPREAD S. Typhi survives in modified phagosomes, avoiding oxidative killing <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line499 to line507>. Macrophages transport the bacteria to lymph nodes, then the bloodstream, causing early bacteremia <Gupta, V. et al. (2021). Standard Treatment Guidelines: [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                            "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                            "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-ENTRY AND INVASION Infection starts via ingestion of contaminated food or water. Typically, 10^5 to 10^6 organisms are required, though food may buffer gastric acid and lower this threshold <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line485 to line493>. In the small intestine, the bacteria target M cells [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "7D7F6754-5FC4-4997-B212-983CCB255548",
                    "stem": "Which neurotransmitter dysregulation is central to NAS?",
                    "explanation": "Norepinephrine dysregulation is central to NAS, causing symptoms like irritability and autonomic instability.",
                    "correct_choice": "Norepinephrine",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Dopamine"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Serotonin"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Norepinephrine"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Acetylcholine"
                        }
                    ],
                    "correct_choice_index": 2,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "NAS symptoms are primarily due to dysregulation of which neurotransmitter?",
                            "correct_choice_index": 2
                        },
                        {
                            "variant_no": 2,
                            "stem": "What neurotransmitter imbalance drives NAS pathophysiology?",
                            "correct_choice_index": 2
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                            "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                            "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-SYSTEMIC SPREAD S. Typhi survives in modified phagosomes, avoiding oxidative killing <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line499 to line507>. Macrophages transport the bacteria to lymph nodes, then the bloodstream, causing early bacteremia <Gupta, V. et al. (2021). Standard Treatment Guidelines: [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                            "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                            "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-ENTRY AND INVASION Infection starts via ingestion of contaminated food or water. Typically, 10^5 to 10^6 organisms are required, though food may buffer gastric acid and lower this threshold <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line485 to line493>. In the small intestine, the bacteria target M cells [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "B75FBFAB-F4D9-47EE-8E75-B8D9E53D56EB",
                    "stem": "What causes autonomic instability in NAS infants?",
                    "explanation": "Opioid withdrawal causes autonomic instability due to increased norepinephrine activity.",
                    "correct_choice": "Opioid withdrawal",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Opioid withdrawal"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Liver dysfunction"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Hypoglycemia"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Vitamin deficiency"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Autonomic instability in NAS is linked to what?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which factor leads to autonomic instability in NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                            "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_6",
                            "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-SYSTEMIC SPREAD S. Typhi survives in modified phagosomes, avoiding oxidative killing <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line499 to line507>. Macrophages transport the bacteria to lymph nodes, then the bloodstream, causing early bacteremia <Gupta, V. et al. (2021). Standard Treatment Guidelines: [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                            "citation_link": "TYPHOID_ENTERICFEVER_ETIOLOGYANDPATHOPHYSIOLOGY_5",
                            "excerpt": "PATHOPHYSIOLOGY-INFECTION PATHWAY-ENTRY AND INVASION Infection starts via ingestion of contaminated food or water. Typically, 10^5 to 10^6 organisms are required, though food may buffer gastric acid and lower this threshold <Kapil, A. et al. (2019). Current antibiotic use in the treatment of enteric fever in children - line485 to line493>. In the small intestine, the bacteria target M cells [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "73F8210E-C4F7-47B0-9AC5-AA81E630C9B5",
            "subtopic_title": "Signs and symptoms of NAS in newborns",
            "sequence_no": 5,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a complex condition arising from withdrawal symptoms in newborns due to in utero exposure to substances, most commonly opioids. The clinical presentation of NAS is characterized by central nervous system hyperirritability, autonomic dysregulation, and gastrointestinal disturbances. Symptoms may include excessive crying, tremors, sleep disturbances, hypertonia, poor feeding, vomiting, diarrhea, and temperature instability. These signs typically manifest within 48–72 hours after birth but may be delayed depending on the type and duration of maternal substance use. Accurate diagnosis relies on a thorough maternal history, clinical observation, and standardized scoring systems such as the Finnegan Neonatal Abstinence Scoring Tool. Supportive care forms the cornerstone of management, emphasizing a quiet environment, swaddling, and frequent feeding to reduce overstimulation. Despite optimal non-pharmacological interventions, approximately 50–80% of opioid-exposed infants may require pharmacological treatment, typically with morphine or methadone, titrated to alleviate withdrawal symptoms. A common pitfall in managing NAS is underestimating the importance of maternal involvement in care. Encouraging maternal participation, such as breastfeeding when appropriate, can improve bonding and neonatal outcomes, provided the mother is not actively using contraindicated substances. Pediatricians must remain vigilant to avoid overdiagnosis, as some symptoms may overlap with other neonatal conditions. A multidisciplinary approach, integrating pediatrics, obstetrics, psychiatry, and social work, is essential for optimizing both neonatal and maternal health outcomes.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                    "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "D00ACDD2-27D4-43CE-8B68-17EEFBE37EB4",
                    "stem": "Which neurological sign is associated with Neonatal Abstinence Syndrome?",
                    "explanation": "Tremors are a common neurological sign in Neonatal Abstinence Syndrome, indicating withdrawal symptoms in affected newborns.",
                    "correct_choice": "Tremors",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Tremors"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Normal reflexes"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Calm demeanor"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Stable movements"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What neurological symptom is seen in NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which neurological feature is typical of NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "33878714-A049-4368-A575-3CDBBB06D304",
                    "stem": "Which symptom is most commonly seen in Neonatal Abstinence Syndrome?",
                    "explanation": "High-pitched crying is a hallmark symptom of Neonatal Abstinence Syndrome, often indicating withdrawal in newborns.",
                    "correct_choice": "High-pitched crying",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "High-pitched crying"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Hypotonia"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Smooth breathing"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Normal feeding"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is a key symptom of NAS in newborns?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which of the following is typical in NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "51111AD4-57F4-48E5-B13A-8F7B418B87A4",
                    "stem": "What feeding difficulty is observed in babies with NAS?",
                    "explanation": "Poor feeding is commonly observed in babies with Neonatal Abstinence Syndrome due to their difficulty in self-regulation.",
                    "correct_choice": "Poor feeding",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Poor feeding"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Rapid feeding"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Normal feeding"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Excessive hunger"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which feeding issue is linked to NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What feeding problem is typical in NAS babies?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "3BC99C47-8B69-4DAA-84B0-B18B61C490D9",
            "subtopic_title": "Diagnosis and screening protocols for NAS",
            "sequence_no": 6,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a significant clinical condition resulting from in utero exposure to substances, most commonly opioids. Accurate and timely diagnosis is crucial to mitigate complications and initiate appropriate interventions. The diagnosis of NAS is primarily clinical, relying on the Finnegan Neonatal Abstinence Scoring System or other validated tools to assess signs of central nervous system hyperirritability, autonomic dysfunction, and gastrointestinal disturbances. Symptoms such as high-pitched crying, tremors, poor feeding, and loose stools typically emerge within the first 72 hours of life but may be delayed depending on the substance involved. Screening protocols for NAS recommend a combination of maternal history, risk factor assessment, and, when indicated, toxicology testing of maternal and/or neonatal samples (urine, meconium, or umbilical cord tissue). Universal screening of all newborns is not routinely recommended; instead, a targeted approach based on maternal risk factors, such as a history of substance use disorder, is emphasized. A common pitfall in diagnosing NAS is the over-reliance on clinical scoring tools without considering differential diagnoses, such as sepsis, hypoglycemia, or metabolic disorders, which can mimic NAS symptoms. This underscores the importance of a thorough clinical evaluation and adjunct investigations to rule out other underlying conditions. Early recognition and a multidisciplinary approach are essential to optimize outcomes for affected neonates and their families.",
            "references": [
                {
                    "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                    "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                    "excerpt": "INTRODUCTION Newborn screening (NBS) is a preventive public health strategy to detect serious but treatable disorders in infants before symptoms appear. It typically involves simple tests done soon after birth – often a heel- prick blood test, along with point-of-care screenings for hearing loss and critical heart defects . Early identification allows timely interventions that can prevent [...]"
                },
                {
                    "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                    "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                    "excerpt": "ERRORS OF METABOLISM) Epidemiology: Congenital hypothyroidism (CH) – failure of the thyroid gland leading to neonatal thyroid hormone deficiency – is one of the most common conditions identified by NBS. Globally, CH occurs in 1 roughly 1 in 3,000–4,000 new borns. In India, the incidence is higher: earlier studies showed about 1 in 2,640 births, and a multi-center ICMR study (2007–2012) [...]"
                },
                {
                    "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                    "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                    "excerpt": "CCHD SCREENING– TARGETED SCREENING Prior to pulse oximetry screening, the traditional approach to detect critical heart defects was through targeted clinical examination and risk factor awareness. In settings where routine pulse ox screening is not done, pediatricians must rely on vigilant physical exams and targeted evaluation of babies with any suspicious signs or risks: 9 (cid:127) [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "0D38A465-1CB6-4294-8A95-2AD2E0FB1209",
                    "stem": "Which test confirms in-utero drug exposure in neonates?",
                    "explanation": "The correct answer is 'Meconium drug testing,' which is a reliable method to confirm in-utero drug exposure.",
                    "correct_choice": "Meconium drug testing",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Meconium drug testing"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "APGAR score assessment"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Pulse oximetry screening"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Hearing screening"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What confirms prenatal substance exposure in neonates?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which test identifies drug exposure in utero?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                            "excerpt": "INTRODUCTION Newborn screening (NBS) is a preventive public health strategy to detect serious but treatable disorders in infants before symptoms appear. It typically involves simple tests done soon after birth – often a heel- prick blood test, along with point-of-care screenings for hearing loss and critical heart defects . Early identification allows timely interventions that can prevent [...]"
                        },
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                            "excerpt": "ERRORS OF METABOLISM) Epidemiology: Congenital hypothyroidism (CH) – failure of the thyroid gland leading to neonatal thyroid hormone deficiency – is one of the most common conditions identified by NBS. Globally, CH occurs in 1 roughly 1 in 3,000–4,000 new borns. In India, the incidence is higher: earlier studies showed about 1 in 2,640 births, and a multi-center ICMR study (2007–2012) [...]"
                        },
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                            "excerpt": "CCHD SCREENING– TARGETED SCREENING Prior to pulse oximetry screening, the traditional approach to detect critical heart defects was through targeted clinical examination and risk factor awareness. In settings where routine pulse ox screening is not done, pediatricians must rely on vigilant physical exams and targeted evaluation of babies with any suspicious signs or risks: 9 (cid:127) [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "76170701-F9DA-4D81-AB0E-31BEE70CCF7B",
                    "stem": "What is the first step in diagnosing Neonatal Abstinence Syndrome?",
                    "explanation": "The correct answer is 'Maternal history of substance use,' as it is the first step in identifying neonates at risk for NAS.",
                    "correct_choice": "Maternal history of substance use",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Maternal history of substance use"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Urine toxicology of the neonate"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Observation for withdrawal signs"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Meconium drug testing"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "How is risk for NAS initially assessed?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What is the primary screening step for NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                            "excerpt": "INTRODUCTION Newborn screening (NBS) is a preventive public health strategy to detect serious but treatable disorders in infants before symptoms appear. It typically involves simple tests done soon after birth – often a heel- prick blood test, along with point-of-care screenings for hearing loss and critical heart defects . Early identification allows timely interventions that can prevent [...]"
                        },
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                            "excerpt": "ERRORS OF METABOLISM) Epidemiology: Congenital hypothyroidism (CH) – failure of the thyroid gland leading to neonatal thyroid hormone deficiency – is one of the most common conditions identified by NBS. Globally, CH occurs in 1 roughly 1 in 3,000–4,000 new borns. In India, the incidence is higher: earlier studies showed about 1 in 2,640 births, and a multi-center ICMR study (2007–2012) [...]"
                        },
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                            "excerpt": "CCHD SCREENING– TARGETED SCREENING Prior to pulse oximetry screening, the traditional approach to detect critical heart defects was through targeted clinical examination and risk factor awareness. In settings where routine pulse ox screening is not done, pediatricians must rely on vigilant physical exams and targeted evaluation of babies with any suspicious signs or risks: 9 (cid:127) [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "B394C241-9569-4009-BB0E-C58AEF8C81D6",
                    "stem": "Which tool is commonly used to assess Neonatal Abstinence Syndrome severity?",
                    "explanation": "The correct answer is 'Finnegan Neonatal Abstinence Scoring System,' which is the most widely used tool to assess NAS severity in neonates.",
                    "correct_choice": "Finnegan Neonatal Abstinence Scoring System",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Finnegan Neonatal Abstinence Scoring System"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "APGAR Score"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Ballard Maturity Assessment"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Denver Developmental Screening Test"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the standard tool for evaluating NAS symptoms?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which scoring system is used for NAS diagnosis?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_0",
                            "excerpt": "INTRODUCTION Newborn screening (NBS) is a preventive public health strategy to detect serious but treatable disorders in infants before symptoms appear. It typically involves simple tests done soon after birth – often a heel- prick blood test, along with point-of-care screenings for hearing loss and critical heart defects . Early identification allows timely interventions that can prevent [...]"
                        },
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_2",
                            "excerpt": "ERRORS OF METABOLISM) Epidemiology: Congenital hypothyroidism (CH) – failure of the thyroid gland leading to neonatal thyroid hormone deficiency – is one of the most common conditions identified by NBS. Globally, CH occurs in 1 roughly 1 in 3,000–4,000 new borns. In India, the incidence is higher: earlier studies showed about 1 in 2,640 births, and a multi-center ICMR study (2007–2012) [...]"
                        },
                        {
                            "source_id": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                            "citation_link": "2_8_Neonatology_Screening_in_the_Newborn_Period_metabolic_hearing_CHD_1_8",
                            "excerpt": "CCHD SCREENING– TARGETED SCREENING Prior to pulse oximetry screening, the traditional approach to detect critical heart defects was through targeted clinical examination and risk factor awareness. In settings where routine pulse ox screening is not done, pediatricians must rely on vigilant physical exams and targeted evaluation of babies with any suspicious signs or risks: 9 (cid:127) [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "ED48C3FC-5BB7-47CF-AC2A-DC3D0255FD46",
            "subtopic_title": "Differential diagnosis of NAS",
            "sequence_no": 7,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a condition resulting from the abrupt discontinuation of in utero exposure to substances, most commonly opioids. The clinical presentation of NAS is often characterized by central nervous system hyperirritability, autonomic dysregulation, and gastrointestinal dysfunction. However, the diagnosis can be challenging due to symptom overlap with other neonatal conditions, necessitating a careful differential diagnosis. Conditions such as sepsis, hypoxic-ischemic encephalopathy, metabolic disorders, and congenital anomalies like intestinal atresia or congenital diaphragmatic hernia (CDH) must be considered. For instance, while NAS may present with irritability, tremors, and feeding difficulties, sepsis could mimic these symptoms but is often accompanied by temperature instability and lethargy. Similarly, CDH presents with respiratory distress immediately after birth, which could be mistaken for autonomic dysregulation in NAS. A thorough maternal history, including substance use during pregnancy, is pivotal, as is the use of standardized scoring systems like the Finnegan Neonatal Abstinence Scoring Tool to assess withdrawal severity. One common pitfall in diagnosing NAS is attributing symptoms solely to withdrawal without ruling out coexisting conditions, such as infections or metabolic abnormalities, which could worsen neonatal outcomes if untreated. A multidisciplinary approach involving neonatologists, social workers, and addiction specialists is essential to ensure accurate diagnosis and holistic management. Recognizing the nuanced presentation of NAS and avoiding premature conclusions are critical to optimizing care for these vulnerable infants.",
            "references": [
                {
                    "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                    "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC WORKUP Most CDH cases present immediately after birth with respiratory distress. Classic signs in the delivery room include cyanosis, tachypnea, and a scaphoid (sunken) abdomen due to abdominal contents in the chest. On examination, the infant may have asymmetrical breath sounds (markedly diminished on the affected side) and heart sounds shifted to the [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                    "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "5B0D8127-7F8D-4E0C-AC61-550B7D5BBE19",
                    "stem": "In differential diagnosis of NAS, which condition commonly presents with jitteriness?",
                    "explanation": "Hypoglycemia commonly presents with jitteriness, which can resemble symptoms of Neonatal Abstinence Syndrome (NAS).",
                    "correct_choice": "Hypoglycemia",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Hypoglycemia"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Cerebral Palsy"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Congenital Syphilis"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Meconium Aspiration Syndrome"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which condition resembling NAS causes jitteriness?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What disorder linked to jitteriness mimics NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC WORKUP Most CDH cases present immediately after birth with respiratory distress. Classic signs in the delivery room include cyanosis, tachypnea, and a scaphoid (sunken) abdomen due to abdominal contents in the chest. On examination, the infant may have asymmetrical breath sounds (markedly diminished on the affected side) and heart sounds shifted to the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "06B08EE2-1673-46DD-8ACE-A3ADB5C8BEB5",
                    "stem": "Which condition can mimic Neonatal Abstinence Syndrome (NAS)?",
                    "explanation": "Sepsis can mimic Neonatal Abstinence Syndrome (NAS) due to overlapping symptoms like irritability and feeding difficulties.",
                    "correct_choice": "Sepsis",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Hypoxic-Ischemic Encephalopathy"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Congenital Heart Disease"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Sepsis"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Infantile Spasms"
                        }
                    ],
                    "correct_choice_index": 2,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What disorder shares symptoms with NAS?",
                            "correct_choice_index": 2
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which diagnosis overlaps clinically with NAS?",
                            "correct_choice_index": 2
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC WORKUP Most CDH cases present immediately after birth with respiratory distress. Classic signs in the delivery room include cyanosis, tachypnea, and a scaphoid (sunken) abdomen due to abdominal contents in the chest. On examination, the infant may have asymmetrical breath sounds (markedly diminished on the affected side) and heart sounds shifted to the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "2B042D5E-05D0-46CE-8F1A-BAFECBCBAD24",
                    "stem": "Which metabolic condition can be confused with NAS due to irritability?",
                    "explanation": "Hypocalcemia can be confused with Neonatal Abstinence Syndrome (NAS) due to irritability as a shared symptom.",
                    "correct_choice": "Hypocalcemia",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Galactosemia"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Phenylketonuria"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Hypocalcemia"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Maple Syrup Urine Disease"
                        }
                    ],
                    "correct_choice_index": 2,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What metabolic disorder mimics NAS symptoms?",
                            "correct_choice_index": 2
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which metabolic issue overlaps clinically with NAS?",
                            "correct_choice_index": 2
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_3",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC WORKUP Most CDH cases present immediately after birth with respiratory distress. Classic signs in the delivery room include cyanosis, tachypnea, and a scaphoid (sunken) abdomen due to abdominal contents in the chest. On examination, the infant may have asymmetrical breath sounds (markedly diminished on the affected side) and heart sounds shifted to the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_10",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSTIC ALGORITHM Newborns with intestinal atresia typically present with feeding intolerance, bilious vomiting, and failure to pass meconium (although some may pass a small amount of meconium if the obstruction is incomplete or very proximal). The timing and nature of symptoms depend on the level of the blockage: - Duodenal atresia: Often presents within the [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "B5DA401C-8468-4A76-A1B4-0BBED54E2493",
            "subtopic_title": "Scoring systems for NAS severity (e.g., Finnegan Neonatal Abstinence Scoring Tool)",
            "sequence_no": 8,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a clinical condition characterized by withdrawal symptoms in newborns due to in utero exposure to substances, most commonly opioids. The Finnegan Neonatal Abstinence Scoring Tool is widely used to assess the severity of NAS and guide management. This tool evaluates multiple domains, including central nervous system hyperirritability (e.g., tremors, excessive crying), autonomic dysfunction (e.g., sweating, fever), and gastrointestinal disturbances (e.g., poor feeding, diarrhea). Scores are assigned based on the intensity of symptoms, with higher cumulative scores indicating more severe withdrawal. International guidelines, such as those from the American Academy of Pediatrics (AAP), recommend using the scoring tool as part of a standardized approach to determine the need for pharmacologic treatment, typically with morphine or methadone, alongside supportive care measures like swaddling and minimizing environmental stimuli. However, in the Indian context, resource limitations and variability in training may affect the consistent application of these scoring systems, leading to underdiagnosis or delayed treatment. A common pitfall in practice is over-reliance on the scoring tool without considering the dynamic nature of withdrawal symptoms, which can fluctuate over time. This underscores the importance of serial assessments rather than a single score to guide treatment decisions. Effective management of NAS requires a multidisciplinary approach, integrating evidence-based protocols with adaptations for local healthcare settings to ensure optimal outcomes for affected neonates.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                },
                {
                    "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                    "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                    "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "EFEA2878-1F22-49AA-B8DB-3D8B97E6F4CB",
                    "stem": "Which scoring tool is most commonly used to assess Neonatal Abstinence Syndrome severity?",
                    "explanation": "The correct answer is 'Finnegan Scoring Tool,' which is the most widely used tool to assess the severity of Neonatal Abstinence Syndrome.",
                    "correct_choice": "Finnegan Scoring Tool",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Finnegan Scoring Tool"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Apgar Score"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Ballard Score"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Silverman-Anderson Score"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the primary tool for evaluating NAS severity?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Identify the most commonly used NAS scoring system.",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                        }
                    ]
                },
                {
                    "question_id": "11F4094A-737E-41B7-87BE-68E2CCE7756A",
                    "stem": "What threshold score on the Finnegan tool often indicates the need for treatment?",
                    "explanation": "The correct answer is '8 or higher,' which typically prompts consideration of pharmacologic treatment for Neonatal Abstinence Syndrome.",
                    "correct_choice": "8 or higher",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "8 or higher"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "5 or higher"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "10 or higher"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "12 or higher"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "On the Finnegan tool, what score suggests treatment is needed?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "A score of what value on the Finnegan tool often warrants intervention?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                        }
                    ]
                },
                {
                    "question_id": "D6A98D84-3DEA-4626-A725-E7BA411D4BF7",
                    "stem": "What is a key feature assessed by the Finnegan Scoring Tool?",
                    "explanation": "The correct answer is 'Excessive crying,' which is a hallmark symptom assessed by the Finnegan Scoring Tool for Neonatal Abstinence Syndrome.",
                    "correct_choice": "Excessive crying",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Excessive crying"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Skin turgor"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Gestational age"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Heart rate variability"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which symptom is evaluated using the Finnegan tool?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "The Finnegan Scoring Tool assesses which key symptom?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "FF13C716-CA4B-4D5B-957B-87FFE3A83B6A",
            "subtopic_title": "Timing and onset of symptoms in NAS",
            "sequence_no": 9,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a clinical condition resulting from the abrupt discontinuation of substances, primarily opioids, to which the newborn was exposed in utero. The timing and onset of symptoms in NAS are influenced by the type of substance involved, its half-life, and the extent of prenatal exposure. For opioids, symptoms typically emerge within 24 to 72 hours after birth, though in cases involving long-acting opioids like methadone or buprenorphine, onset may be delayed up to 5 to 7 days. Clinically, NAS manifests as central nervous system hyperirritability (e.g., tremors, high-pitched crying, seizures), autonomic dysregulation (e.g., sweating, fever), and gastrointestinal dysfunction (e.g., poor feeding, diarrhea). Early identification and monitoring using validated scoring systems, such as the Finnegan Neonatal Abstinence Scoring Tool, are essential for timely intervention. First-line management prioritizes non-pharmacological measures, including creating a calm environment, promoting skin-to-skin contact, and supporting breastfeeding when safe. These strategies not only mitigate symptoms but also strengthen maternal-infant bonding. A common pitfall in clinical practice is prematurely initiating pharmacological treatment without fully optimizing non-pharmacological care, which can prolong hospital stays and increase medication exposure. Careful discharge planning is crucial, as these infants are at heightened risk for developmental challenges and require coordinated follow-up across multiple disciplines. Understanding the variable onset of symptoms and emphasizing supportive care are key to improving outcomes in this vulnerable population.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "A08FD110-ADE5-45EB-A379-889A070095D0",
                    "stem": "What is the typical onset of symptoms in Neonatal Abstinence Syndrome (NAS) for infants exposed to opioids in utero?",
                    "explanation": "Symptoms of Neonatal Abstinence Syndrome (NAS) typically begin 24–72 hours after birth for infants exposed to opioids in utero.",
                    "correct_choice": "24–72 hours after birth",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Within 24 hours of birth"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "24–72 hours after birth"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "5–7 days after birth"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "10–14 days after birth"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "When do symptoms of NAS usually appear in opioid-exposed neonates?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "For infants exposed to opioids, when does NAS symptom onset typically occur?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "AAADB0F9-D20C-46FD-91E3-A93C6367516E",
                    "stem": "Which factor most influences the timing of NAS symptom onset?",
                    "explanation": "The timing of NAS symptom onset is most influenced by the type of substance used, with opioids typically causing symptoms within 24–72 hours after birth.",
                    "correct_choice": "Type of substance used",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Type of substance used"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Infant's birth weight"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Maternal age"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Mode of delivery"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What primarily determines the timing of NAS symptoms?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which factor is key in NAS symptom timing?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "A2B73DE4-B098-4BDB-B47C-FDC7D3FF038A",
                    "stem": "Delayed onset of NAS symptoms is most commonly associated with exposure to which substance?",
                    "explanation": "Delayed onset of NAS symptoms is most commonly associated with methadone, which may cause symptoms to appear up to 5–7 days after birth.",
                    "correct_choice": "Methadone",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Heroin"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Methadone"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Cocaine"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Alcohol"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which substance is linked to delayed NAS symptom onset?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "Methadone exposure in neonates is linked to what timing of NAS symptom onset?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "5ECA6885-DACB-4AFD-9D99-74D5DB4A9389",
            "subtopic_title": "Pharmacological treatment options (e.g., morphine, methadone, buprenorphine)",
            "sequence_no": 10,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a complex condition resulting from in utero exposure to opioids, requiring a multidisciplinary approach to management. While non-pharmacological interventions such as optimizing the infant’s environment, promoting breastfeeding, and providing skin-to-skin contact are the first-line strategies, approximately 50–80% of opioid-exposed neonates ultimately require pharmacological treatment to alleviate severe withdrawal symptoms. International guidelines, including those from the American Academy of Pediatrics (AAP), recommend morphine and methadone as the primary pharmacological agents due to their efficacy in controlling symptoms like irritability, feeding difficulties, and autonomic instability. Buprenorphine, though less commonly used, is emerging as a promising alternative due to its longer half-life and potential for fewer dosing adjustments. The choice of medication should be guided by institutional protocols, the severity of symptoms, and the infant’s clinical response, with regular monitoring using standardized scoring tools such as the Finnegan Neonatal Abstinence Scoring System.\n\nA key pitfall in pharmacological management is over-reliance on medication without adequately addressing non-pharmacological measures. This can prolong hospital stays and increase the risk of complications such as feeding intolerance or developmental delays. Effective management also requires maternal counseling and support, as the caregiver’s involvement significantly impacts the infant’s recovery trajectory. In resource-limited settings, adapting international guidelines to local contexts, including the availability of medications and social support systems, is crucial for optimizing outcomes. NAS remains a challenging condition that underscores the importance of integrating medical, social, and psychological care for both the infant and the family.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "911080CA-10D7-475A-8D44-9FB11D0BD2B2",
                    "stem": "Which medication is first-line for treating neonatal abstinence syndrome?",
                    "explanation": "Morphine is the first-line pharmacological treatment for neonatal abstinence syndrome due to its efficacy in alleviating withdrawal symptoms.",
                    "correct_choice": "Morphine",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Morphine"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Methadone"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Buprenorphine"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Phenobarbital"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the preferred initial treatment for neonatal abstinence syndrome?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which drug is commonly used first in neonatal abstinence syndrome?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "D97E9921-F4A6-4EA4-8ACF-B21B4318F041",
                    "stem": "Which medication is less commonly used but effective for neonatal abstinence syndrome?",
                    "explanation": "Buprenorphine is less commonly used but effective for treating neonatal abstinence syndrome, especially in certain clinical settings.",
                    "correct_choice": "Buprenorphine",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Methadone"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Buprenorphine"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Clonidine"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Phenobarbital"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What less common drug is effective for neonatal abstinence syndrome?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which less frequently used medication can treat neonatal abstinence syndrome?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "E9B1B0A8-9FE2-4611-A87B-C0C7FB76F58C",
                    "stem": "Which medication is an alternative to morphine for neonatal abstinence syndrome?",
                    "explanation": "Methadone is an alternative to morphine for treating neonatal abstinence syndrome, offering similar efficacy in managing withdrawal symptoms.",
                    "correct_choice": "Methadone",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Phenobarbital"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Methadone"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Clonidine"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Buprenorphine"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is a second-line option after morphine for neonatal abstinence syndrome?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which drug can replace morphine in neonatal abstinence syndrome management?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "52867C6C-E88A-494D-BCB1-C256CA47D8F9",
            "subtopic_title": "Non-pharmacological management strategies (e.g., swaddling, soothing techniques)",
            "sequence_no": 11,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a withdrawal syndrome in newborns resulting from in utero exposure to substances, most commonly opioids. Non-pharmacological management is the cornerstone of initial care and focuses on optimizing the infant’s environment to reduce withdrawal symptoms and promote neurodevelopmental stability. Creating a calm, low-stimulus environment is essential. This can be achieved by dimming lights, minimizing noise, and clustering care to avoid overstimulation. Swaddling is a widely used technique to provide the infant with a sense of security and containment, mimicking the intrauterine environment. Skin-to-skin contact, or kangaroo care, not only soothes the baby but also fosters bonding and stabilizes physiological parameters such as heart rate and temperature. Additionally, soothing techniques like gentle rocking and the use of pacifiers can help mitigate irritability and promote self-soothing behaviors. Feeding on demand, with attention to the infant's cues, is encouraged to ensure adequate nutrition and hydration, as NAS infants often have difficulty with feeding due to increased energy expenditure and irritability.\n\nOne common pitfall in non-pharmacological management is the inconsistency in care practices among caregivers. For example, variations in swaddling techniques or environmental control can inadvertently exacerbate the infant's symptoms. To avoid this, a standardized approach should be implemented, with all caregivers trained in evidence-based supportive strategies. While non-pharmacological methods are the first-line approach, ongoing assessment is crucial, as some infants may still require pharmacological intervention to manage severe symptoms.",
            "references": [
                {
                    "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                    "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                    "excerpt": "COMPREHENSIVE AND LONGITUDINAL CARE OF PRETERM INFANTS Caring for a preterm infant extends beyond managing individual complications – it requires a holistic, longitudinal approach that starts from birth and continues through childhood. Indian pediatricians must integrate preventive, supportive, and monitoring strategies to improve survival and neurodevelopmental outcomes of preterm babies. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                    "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                },
                {
                    "source_id": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                    "citation_link": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                    "excerpt": "INTRODUCTION Neonatal respiratory support is a critical skill in the Level II NICU setting, where many infants develop respiratory distress soon after birth. Respiratory distress occurs in about 7% of term neonates and an even higher percentage of preterm infants. Common causes include transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS) due to surfactant deficiency [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "412D4ABB-E297-4F2E-A021-70E30077E33F",
                    "stem": "What environmental adjustment benefits NAS neonates?",
                    "explanation": "Dim lighting helps create a calm environment for neonates with NAS.",
                    "correct_choice": "Dim lighting",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Dim lighting"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Bright colors"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Frequent disruptions"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Loud background noise"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which environmental change soothes NAS infants?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What adjustment creates a calming space for NAS neonates?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                            "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                            "excerpt": "COMPREHENSIVE AND LONGITUDINAL CARE OF PRETERM INFANTS Caring for a preterm infant extends beyond managing individual complications – it requires a holistic, longitudinal approach that starts from birth and continues through childhood. Indian pediatricians must integrate preventive, supportive, and monitoring strategies to improve survival and neurodevelopmental outcomes of preterm babies. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                        },
                        {
                            "source_id": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                            "citation_link": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                            "excerpt": "INTRODUCTION Neonatal respiratory support is a critical skill in the Level II NICU setting, where many infants develop respiratory distress soon after birth. Respiratory distress occurs in about 7% of term neonates and an even higher percentage of preterm infants. Common causes include transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS) due to surfactant deficiency [...]"
                        }
                    ]
                },
                {
                    "question_id": "86FE78E0-3CBF-46EC-85DD-9B483C52B159",
                    "stem": "Which non-pharmacological strategy helps soothe a neonate with NAS?",
                    "explanation": "Swaddling helps provide comfort and reduces overstimulation in neonates with NAS.",
                    "correct_choice": "Swaddling",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Swaddling"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Bright lighting"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Frequent repositioning"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Loud white noise"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is an effective calming method for NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which technique reduces overstimulation in NAS infants?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                            "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                            "excerpt": "COMPREHENSIVE AND LONGITUDINAL CARE OF PRETERM INFANTS Caring for a preterm infant extends beyond managing individual complications – it requires a holistic, longitudinal approach that starts from birth and continues through childhood. Indian pediatricians must integrate preventive, supportive, and monitoring strategies to improve survival and neurodevelopmental outcomes of preterm babies. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                        },
                        {
                            "source_id": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                            "citation_link": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                            "excerpt": "INTRODUCTION Neonatal respiratory support is a critical skill in the Level II NICU setting, where many infants develop respiratory distress soon after birth. Respiratory distress occurs in about 7% of term neonates and an even higher percentage of preterm infants. Common causes include transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS) due to surfactant deficiency [...]"
                        }
                    ]
                },
                {
                    "question_id": "B18E0173-1ED0-4BE9-9E08-F88197F67C02",
                    "stem": "How can caregivers reduce overstimulation in NAS infants?",
                    "explanation": "Soothing techniques help reduce overstimulation and promote relaxation in NAS infants.",
                    "correct_choice": "Soothing techniques",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Soothing techniques"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Frequent handling"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Brightly colored toys"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Loud music"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which approach promotes relaxation in NAS infants?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What strategy minimizes overstimulation in NAS neonates?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                            "citation_link": "2_2_Neonatology_Care_of_Preterm_Infants_nutrition_J_RDS_J_NEC_J_IVH_5",
                            "excerpt": "COMPREHENSIVE AND LONGITUDINAL CARE OF PRETERM INFANTS Caring for a preterm infant extends beyond managing individual complications – it requires a holistic, longitudinal approach that starts from birth and continues through childhood. Indian pediatricians must integrate preventive, supportive, and monitoring strategies to improve survival and neurodevelopmental outcomes of preterm babies. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                        },
                        {
                            "source_id": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                            "citation_link": "2_5_Neonatology_Neonatal_Ventilation_CPAP_0",
                            "excerpt": "INTRODUCTION Neonatal respiratory support is a critical skill in the Level II NICU setting, where many infants develop respiratory distress soon after birth. Respiratory distress occurs in about 7% of term neonates and an even higher percentage of preterm infants. Common causes include transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS) due to surfactant deficiency [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "39A6E67B-2FB6-4348-AA9F-35AEA7565704",
            "subtopic_title": "Nutritional care for infants with NAS",
            "sequence_no": 12,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a complex condition arising from in utero exposure to substances, most commonly opioids, and is characterized by central nervous system hyperirritability, autonomic dysfunction, and gastrointestinal disturbances. Nutritional care plays a pivotal role in managing infants with NAS, as effective feeding can help mitigate symptoms and promote growth. First-line management emphasizes non-pharmacological strategies, including optimizing the infant’s environment and care. Breastfeeding is strongly encouraged when maternal substance use is appropriately managed, as it can provide comfort, reduce withdrawal severity, and strengthen maternal-infant bonding. However, careful assessment of maternal substance use is crucial to ensure the safety of breast milk. For infants who struggle with feeding due to irritability or poor coordination, smaller, more frequent feeds can be beneficial. High-calorie formulas may be considered for those with significant weight loss or poor growth. A calm, low-stimulation feeding environment is essential to reduce stress and improve feeding outcomes.\n\nOne common pitfall in nutritional care is overlooking the importance of maternal counseling and support. Effective management of NAS requires addressing the broader social and psychological needs of the mother, including substance use treatment and parenting support. Failure to engage the mother in the infant’s care plan can lead to inconsistent feeding practices and hinder recovery. Discharge planning should include clear nutritional guidelines and follow-up care to monitor growth and developmental progress, ensuring a smoother transition to home. Recognizing the interconnected needs of the infant and mother is key to achieving optimal outcomes in NAS management.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "F8ADABF5-AA98-46FF-8691-5B1CEB13EC8C",
                    "stem": "Which nutrient is often prioritized for NAS infants due to their increased metabolic demands?",
                    "explanation": "High-calorie formula is often prioritized to meet the increased metabolic demands and support growth in infants with NAS.",
                    "correct_choice": "High-calorie formula",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "High-calorie formula"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Low-fat milk"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Water supplementation"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Electrolyte solutions"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What type of nutrition is emphasized for NAS infants to support growth?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "For infants with NAS, what nutritional intervention is commonly used to address their metabolic needs?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "4BA80FE7-E3C2-437A-A329-CA86A6AEC451",
                    "stem": "What is the preferred feeding method for infants with Neonatal Abstinence Syndrome (NAS)?",
                    "explanation": "Breastfeeding if maternal drug-free is preferred as it provides comfort and nutrition while promoting bonding, provided the mother is not using contraindicated substances.",
                    "correct_choice": "Breastfeeding if maternal drug-free",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Breastfeeding if maternal drug-free"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Formula feeding only"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Tube feeding for all cases"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "No feeding restrictions"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which feeding method is encouraged for NAS infants if the mother is eligible?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "For infants with NAS, which feeding approach is recommended under appropriate maternal conditions?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "06B10F22-FFDE-4131-97F6-F8686598E42A",
                    "stem": "How can frequent, small feedings benefit NAS infants?",
                    "explanation": "Frequent, small feedings reduce feeding intolerance by minimizing gastrointestinal distress, which is common in NAS infants.",
                    "correct_choice": "Reduce feeding intolerance",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Reduce feeding intolerance"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Increase caloric intake"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Promote faster weaning"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Prevent dehydration"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is a key benefit of small, frequent feedings for NAS infants?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Why are small, frequent feedings recommended for infants with NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "D5E723D7-2D35-46FA-9DD0-5D3A803CFD80",
            "subtopic_title": "Impact of NAS on neurodevelopment and long-term outcomes",
            "sequence_no": 13,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a complex neurobehavioral condition primarily resulting from in utero exposure to opioids, though other substances may contribute. The central nervous system hyperirritability seen in these newborns—manifesting as tremors, excessive crying, poor feeding, and sleep disturbances—can have significant implications for neurodevelopment. Long-term outcomes for infants with NAS are influenced by various factors, including the severity of withdrawal symptoms, the presence of co-exposures (e.g., alcohol, tobacco), and the quality of postnatal care. Studies suggest that children with NAS may face challenges such as delayed cognitive and motor milestones, attention deficits, and behavioral dysregulation, underscoring the importance of early intervention services. While pharmacological management, typically with morphine or methadone, is often necessary for 50–80% of opioid-exposed infants, over-reliance on medication without optimizing non-pharmacological care—such as swaddling, skin-to-skin contact, and minimizing environmental stimuli—remains a common pitfall. Supportive care can significantly reduce the severity of symptoms and the duration of pharmacotherapy. Follow-up care is equally critical, as the neurodevelopmental trajectory of these infants may require ongoing monitoring and support. Pediatricians should collaborate with developmental specialists and social services to address potential delays and environmental risks, particularly in low-resource settings where challenges such as limited access to neonatal care and stigma may exacerbate outcomes. A multidisciplinary approach is essential to improving both short- and long-term outcomes for these vulnerable infants.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                    "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                    "excerpt": "FOLLOW-UP AND OUTCOMES Managing neonatal sepsis does not end with acute treatment; follow-up is crucial to ensure the baby’s complete recovery and to address any complications or sequelae of the infection. Additionally, given the high stakes, efforts must be made to prevent recurrence and to improve long-term outcomes for the infant. In-hospital follow-up and monitoring: During and after [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                    "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                    "excerpt": "VARIANTS AND CHALLENGES IN LOW-RESOURCE SETTINGS (INDIA CONTEXT) In India and other low-resource settings, several challenges and unique scenarios are observed in CDH management: (cid:127) Late or Missed Diagnosis: While most CDH presents in the first hours of life, there are instances of late-presenting CDH in infants or children. These are often Morgagni hernias or small Bochdalek defects [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "AF1A48BF-2925-4433-BEB9-777525FCD238",
                    "stem": "What is a known long-term outcome of NAS?",
                    "explanation": "Behavioral problems are a known long-term outcome of NAS, often linked to prenatal opioid exposure and postnatal environmental influences.",
                    "correct_choice": "Behavioral problems",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Behavioral problems"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Improved academic performance"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Decreased risk of ADHD"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Enhanced motor skills"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which long-term issue is linked to NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Children with NAS are at risk for which long-term outcome?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                            "excerpt": "FOLLOW-UP AND OUTCOMES Managing neonatal sepsis does not end with acute treatment; follow-up is crucial to ensure the baby’s complete recovery and to address any complications or sequelae of the infection. Additionally, given the high stakes, efforts must be made to prevent recurrence and to improve long-term outcomes for the infant. In-hospital follow-up and monitoring: During and after [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                            "excerpt": "VARIANTS AND CHALLENGES IN LOW-RESOURCE SETTINGS (INDIA CONTEXT) In India and other low-resource settings, several challenges and unique scenarios are observed in CDH management: (cid:127) Late or Missed Diagnosis: While most CDH presents in the first hours of life, there are instances of late-presenting CDH in infants or children. These are often Morgagni hernias or small Bochdalek defects [...]"
                        }
                    ]
                },
                {
                    "question_id": "3C7C7768-AF12-4220-B51F-9867BC0B253A",
                    "stem": "How does NAS typically affect academic performance later in life?",
                    "explanation": "Lower achievement scores are typically seen in children with NAS, reflecting the impact of early-life challenges on cognitive and educational outcomes.",
                    "correct_choice": "Lower achievement scores",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Lower achievement scores"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Higher grades overall"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "No significant impact"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Improved focus in school"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the typical academic outcome of NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "NAS is associated with which academic trend later in life?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                            "excerpt": "FOLLOW-UP AND OUTCOMES Managing neonatal sepsis does not end with acute treatment; follow-up is crucial to ensure the baby’s complete recovery and to address any complications or sequelae of the infection. Additionally, given the high stakes, efforts must be made to prevent recurrence and to improve long-term outcomes for the infant. In-hospital follow-up and monitoring: During and after [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                            "excerpt": "VARIANTS AND CHALLENGES IN LOW-RESOURCE SETTINGS (INDIA CONTEXT) In India and other low-resource settings, several challenges and unique scenarios are observed in CDH management: (cid:127) Late or Missed Diagnosis: While most CDH presents in the first hours of life, there are instances of late-presenting CDH in infants or children. These are often Morgagni hernias or small Bochdalek defects [...]"
                        }
                    ]
                },
                {
                    "question_id": "81A5D2FB-2BE0-41DA-8250-BB18EF033D9A",
                    "stem": "Which neurodevelopmental issue is most commonly associated with Neonatal Abstinence Syndrome (NAS)?",
                    "explanation": "Cognitive delays are most commonly associated with Neonatal Abstinence Syndrome (NAS), often due to prenatal opioid exposure and environmental factors.",
                    "correct_choice": "Cognitive delays",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Cognitive delays"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Motor deficits"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Hearing impairment"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Visual impairment"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the most frequent neurodevelopmental outcome in children with NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Children with NAS most often experience which developmental issue?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_10",
                            "excerpt": "FOLLOW-UP AND OUTCOMES Managing neonatal sepsis does not end with acute treatment; follow-up is crucial to ensure the baby’s complete recovery and to address any complications or sequelae of the infection. Additionally, given the high stakes, efforts must be made to prevent recurrence and to improve long-term outcomes for the infant. In-hospital follow-up and monitoring: During and after [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_7",
                            "excerpt": "VARIANTS AND CHALLENGES IN LOW-RESOURCE SETTINGS (INDIA CONTEXT) In India and other low-resource settings, several challenges and unique scenarios are observed in CDH management: (cid:127) Late or Missed Diagnosis: While most CDH presents in the first hours of life, there are instances of late-presenting CDH in infants or children. These are often Morgagni hernias or small Bochdalek defects [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "71C2EEBB-D4DD-4A27-A415-89784B77B4F3",
            "subtopic_title": "Role of breastfeeding in NAS management",
            "sequence_no": 14,
            "concept": "Breastfeeding plays a pivotal role in the management of Neonatal Abstinence Syndrome (NAS), offering both nutritional and therapeutic benefits. International guidelines, including those from the American Academy of Pediatrics (AAP), emphasize breastfeeding as a cornerstone of non-pharmacological management for NAS, provided the mother is stable and adherent to a supervised treatment program. Breast milk contains small amounts of opioids or other substances the infant may have been exposed to in utero, which can help alleviate withdrawal symptoms by providing a gradual weaning effect. Additionally, breastfeeding fosters maternal-infant bonding, stabilizes the infant’s environment, and reduces stress, all of which contribute to improved outcomes. In the Indian context, where breastfeeding rates are traditionally high, this practice can be effectively leveraged, though challenges such as stigma, lack of maternal counseling, and limited access to lactation support may hinder its implementation. A key pitfall often observed is the premature discouragement of breastfeeding due to misconceptions about substance use during lactation. This can deprive the infant of its benefits and escalate the severity of withdrawal symptoms, necessitating pharmacological interventions. Comprehensive maternal counseling is essential to address these concerns, ensuring that mothers are informed, supported, and monitored. Ultimately, breastfeeding, when safely practiced, is a low-cost, high-impact intervention that aligns with the first-line strategy of optimizing the infant's environment and care in NAS management.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "D942DEF6-62D7-4FA4-B0B5-2412E5786EFE",
                    "stem": "How does breast milk affect pharmacologic treatment in NAS?",
                    "explanation": "Breast milk 'reduces medication requirement' in NAS by alleviating withdrawal symptoms naturally.",
                    "correct_choice": "Reduces medication requirement",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Reduces medication requirement"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Increases medication requirement"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Eliminates medication need"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Has no effect on treatment"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the impact of breast milk on pharmacologic therapy in NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "How does breastfeeding influence the need for medication in NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "AC077E82-0197-43AC-A4D6-7917BF31B588",
                    "stem": "What is the primary benefit of breastfeeding in neonatal abstinence syndrome (NAS)?",
                    "explanation": "Breastfeeding is recommended because it 'reduces NAS symptom severity' and supports maternal-infant bonding.",
                    "correct_choice": "Reduces NAS symptom severity",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Reduces NAS symptom severity"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Prevents NAS entirely"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Eliminates need for medication"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Shortens hospital stay by half"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "How does breastfeeding help manage neonatal abstinence syndrome (NAS)?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What is a key advantage of breastfeeding for infants with NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "E6E7B1DD-AEC5-4011-A5EE-99B96BCE0E0B",
                    "stem": "Which maternal factor contraindicates breastfeeding in NAS management?",
                    "explanation": "Breastfeeding is contraindicated in cases of 'active illicit drug use' due to potential harm to the infant.",
                    "correct_choice": "Active illicit drug use",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Active illicit drug use"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "History of NAS"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Premature birth"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Maternal anemia"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "In NAS management, when is breastfeeding not recommended?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What disqualifies a mother from breastfeeding an infant with NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "240930A5-E4DD-4B2B-B151-2F55423BEE21",
            "subtopic_title": "Maternal education and counseling for substance use during pregnancy",
            "sequence_no": 15,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a multifaceted clinical condition resulting from in utero exposure to substances, most commonly opioids, which leads to withdrawal symptoms in the newborn after birth. Effective management of NAS extends beyond treating the infant; it necessitates addressing maternal substance use through education and counseling during pregnancy. Maternal counseling should focus on fostering understanding of the risks associated with prenatal substance exposure, including NAS, preterm birth, and developmental delays. Educating mothers about the importance of seeking timely treatment for substance use disorders, such as medication-assisted therapy (MAT) with methadone or buprenorphine, is critical. Counseling should also emphasize harm reduction strategies, such as avoiding polysubstance use and maintaining prenatal care appointments. A multidisciplinary approach, incorporating obstetricians, pediatricians, social workers, and addiction specialists, can optimize outcomes for both mother and child. One common pitfall is the failure to address the stigma associated with substance use during pregnancy, which may deter mothers from seeking care. Creating a nonjudgmental and supportive environment is essential to building trust and encouraging engagement. Additionally, maternal education should integrate discussions about postnatal care, including breastfeeding, which can mitigate NAS symptoms in opioid-exposed infants. By prioritizing maternal education and counseling, healthcare providers can play a pivotal role in reducing the incidence and severity of NAS while supporting long-term maternal and neonatal health.",
            "references": [
                {
                    "source_id": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                    "citation_link": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                    "excerpt": "IYCF GUIDELINES IMPLEMENTATION AND COUNSELING Implementing the Infant and Young Child Feeding (IYCF) guidelines requires both program design at high level and practical counseling at the ground level. On the program side, the IYCF 19 guidelines are disseminated through government channels to all states – often through workshops and the creation of state-level IYCF cells or committees. [...]"
                },
                {
                    "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                    "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                    "excerpt": "ETIOLOGY AND CAUSATIVE ORGANISMS EARLY-ONSET SEPSIS (EOS) Neonatal sepsis can be caused by a broad array of organisms – bacteria are the most common cause, but fungi and viruses are also significant contributors. The spectrum of causative pathogens in India shows important differences from Western countries, and it varies between early- and late-onset sepsis. EOS is typically due to [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "136C9ED3-F273-45E9-9611-39E0CD9A7214",
                    "stem": "What should maternal education on substance use during pregnancy emphasize?",
                    "explanation": "Maternal education should emphasize 'risks to the fetus and mother' to help women make informed decisions about their health.",
                    "correct_choice": "Risks to the fetus and mother",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Risks to the fetus and mother"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Legal consequences of substance use"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Mandatory detoxification programs"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Immediate cessation without support"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the main focus of educating pregnant women about substance use?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What should be highlighted in substance use education for pregnant women?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                            "citation_link": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                            "excerpt": "IYCF GUIDELINES IMPLEMENTATION AND COUNSELING Implementing the Infant and Young Child Feeding (IYCF) guidelines requires both program design at high level and practical counseling at the ground level. On the program side, the IYCF 19 guidelines are disseminated through government channels to all states – often through workshops and the creation of state-level IYCF cells or committees. [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                            "excerpt": "ETIOLOGY AND CAUSATIVE ORGANISMS EARLY-ONSET SEPSIS (EOS) Neonatal sepsis can be caused by a broad array of organisms – bacteria are the most common cause, but fungi and viruses are also significant contributors. The spectrum of causative pathogens in India shows important differences from Western countries, and it varies between early- and late-onset sepsis. EOS is typically due to [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "41092A61-7FDB-4F86-9382-683FB9862515",
                    "stem": "Which approach is most effective in counseling pregnant women about substance use?",
                    "explanation": "The most effective approach is 'supportive and nonjudgmental care,' which fosters trust and encourages women to seek help.",
                    "correct_choice": "Supportive and nonjudgmental care",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Punitive and strict measures"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Supportive and nonjudgmental care"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Immediate hospitalization for detox"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Focus on neonatal outcomes only"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the most beneficial strategy for counseling pregnant women with substance use?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "What counseling method works best for pregnant women with substance use disorder?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                            "citation_link": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                            "excerpt": "IYCF GUIDELINES IMPLEMENTATION AND COUNSELING Implementing the Infant and Young Child Feeding (IYCF) guidelines requires both program design at high level and practical counseling at the ground level. On the program side, the IYCF 19 guidelines are disseminated through government channels to all states – often through workshops and the creation of state-level IYCF cells or committees. [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                            "excerpt": "ETIOLOGY AND CAUSATIVE ORGANISMS EARLY-ONSET SEPSIS (EOS) Neonatal sepsis can be caused by a broad array of organisms – bacteria are the most common cause, but fungi and viruses are also significant contributors. The spectrum of causative pathogens in India shows important differences from Western countries, and it varies between early- and late-onset sepsis. EOS is typically due to [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "44F27635-2472-44B3-B2B9-9513EC0BF1C6",
                    "stem": "What is the primary goal of counseling pregnant women with substance use disorder?",
                    "explanation": "The primary goal of counseling is to 'promote maternal and fetal health' by addressing substance use in a supportive and nonjudgmental manner.",
                    "correct_choice": "Promote maternal and fetal health",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Prevent neonatal abstinence syndrome"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Promote maternal and fetal health"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Encourage immediate cessation of substance use"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Focus on legal consequences of drug use"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What is the key focus of educating pregnant women with substance use disorder?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "What is the main objective of counseling expectant mothers using substances?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                            "citation_link": "2_7_Neonatology_Breastfeeding_Support_Lactation_Management_1_10",
                            "excerpt": "IYCF GUIDELINES IMPLEMENTATION AND COUNSELING Implementing the Infant and Young Child Feeding (IYCF) guidelines requires both program design at high level and practical counseling at the ground level. On the program side, the IYCF 19 guidelines are disseminated through government channels to all states – often through workshops and the creation of state-level IYCF cells or committees. [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_2",
                            "excerpt": "ETIOLOGY AND CAUSATIVE ORGANISMS EARLY-ONSET SEPSIS (EOS) Neonatal sepsis can be caused by a broad array of organisms – bacteria are the most common cause, but fungi and viruses are also significant contributors. The spectrum of causative pathogens in India shows important differences from Western countries, and it varies between early- and late-onset sepsis. EOS is typically due to [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "20984DAB-07C9-4C72-B025-5B23BCE3B3DA",
            "subtopic_title": "Multidisciplinary approach to NAS care (e.g., neonatologists, social workers)",
            "sequence_no": 16,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a complex condition requiring a multidisciplinary approach that integrates pediatrics, obstetrics, psychiatry, and social work to optimize outcomes for both the infant and the family. The cornerstone of NAS management is non-pharmacological care, which focuses on creating a supportive environment tailored to the infant's needs. This includes minimizing sensory stimulation, promoting skin-to-skin contact, encouraging breastfeeding when appropriate, and fostering maternal-infant bonding. Pharmacological therapy, typically with opioids such as morphine or methadone, is reserved for severe cases where symptoms like feeding difficulties or weight loss persist despite supportive care. Effective NAS care extends beyond the infant to include maternal counseling and addressing social and legal considerations. Supporting the mother’s mental health, substance use treatment, and parenting skills is vital, as maternal well-being directly impacts the infant’s recovery and long-term development. Social workers play a critical role in coordinating services, ensuring safe discharge planning, and addressing barriers such as housing instability or lack of access to healthcare. One common pitfall in NAS care is the over-reliance on pharmacological treatment without fully implementing or optimizing non-pharmacological interventions, which can unnecessarily prolong hospitalization and delay bonding. Discharge planning should be meticulous, involving clear communication with primary care providers and ensuring follow-up for developmental surveillance. By addressing both medical and psychosocial needs, a multidisciplinary team can improve outcomes for infants and their families.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                    "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                    "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "882C4B9F-6215-435B-9397-7F4BEC30E4D0",
                    "stem": "Which team member arranges post-discharge community resources for NAS families?",
                    "explanation": "The social worker arranges post-discharge community resources for NAS families, ensuring ongoing support and care after hospital discharge.",
                    "correct_choice": "Social worker",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Neonatologist"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Social worker"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Occupational therapist"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Pediatric nurse"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Who coordinates post-discharge resources for NAS care?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "Who links NAS families to community resources?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "235C0F29-8D41-445F-B17B-A44E1909158D",
                    "stem": "What is the neonatologist's primary role in NAS care?",
                    "explanation": "The neonatologist's primary role in NAS care is managing withdrawal symptoms, ensuring the infant's medical stability and comfort.",
                    "correct_choice": "Managing withdrawal symptoms",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Managing withdrawal symptoms"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Providing family counseling"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Coordinating foster care"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Administering vaccinations"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What does the neonatologist focus on in NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What is the neonatologist responsible for in NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "F24E8944-AC7B-410D-8012-A7B358ED6A35",
                    "stem": "Which professional is essential for addressing family dynamics in NAS care?",
                    "explanation": "A social worker is essential for addressing family dynamics in NAS care, as they provide support and resources to families affected by the condition.",
                    "correct_choice": "Social worker",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Neonatologist"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Social worker"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Pharmacist"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Respiratory therapist"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Who provides family support in NAS care?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "Who helps families navigate NAS challenges?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_2",
                            "excerpt": "MANAGEMENT Management of NAS involves a combination of non-pharmacological (supportive) care for all affected infants and pharmacological therapy for those with moderate to severe withdrawal that cannot be calmed by supportive measures. The overarching goals are to ensure the infant achieves adequate sleep, nutrition, and comfort to grow and develop normally, while preventing complications [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_6",
                            "excerpt": "FOLLOW-UP CASE AND DISCHARGE PLANNING Careful planning for discharge and follow-up is essential for infants who have experienced NAS, as well as for their mothers or primary caregivers. Key aspects include determining the appropriate timing of discharge, arranging continuity of care for ongoing needs (medical and social), and educating caregivers. Duration of Hospital Observation: Infants [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "ED840D05-AEFC-4327-8619-44B0475D083C",
            "subtopic_title": "Prevention strategies for NAS (e.g., maternal substance use treatment programs)",
            "sequence_no": 17,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a complex condition resulting from in utero exposure to substances, most commonly opioids, and manifests as withdrawal symptoms in the newborn. Prevention strategies for NAS are rooted in addressing maternal substance use during pregnancy, emphasizing the importance of comprehensive maternal care. Maternal substance use treatment programs, including Medication-Assisted Treatment (MAT) with methadone or buprenorphine, are central to reducing the severity of NAS and improving neonatal outcomes. These programs should be integrated with prenatal care and include counseling, social support, and mental health services to address co-occurring conditions. Early identification of substance use through non-judgmental screening during pregnancy is crucial. However, a common pitfall is the stigmatization of mothers, which can deter them from seeking help. This underscores the need for a supportive, multidisciplinary approach that combines obstetric, pediatric, and psychiatric expertise. Legal considerations, such as mandatory reporting of substance use, must be balanced with efforts to build trust and ensure the safety of both mother and baby. For infants born at risk of NAS, non-pharmacological interventions like rooming-in, breastfeeding (when safe), and minimizing environmental stressors are first-line strategies to reduce withdrawal symptoms. Effective prevention of NAS requires a dual focus: managing maternal substance use while fostering a nurturing environment for the newborn.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                    "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "75ECAA45-5809-41FC-A43A-488DAFFFB444",
                    "stem": "Which approach reduces the risk of NAS in infants?",
                    "explanation": "The correct answer is 'Maternal substance use treatment programs,' as these programs help prevent NAS by addressing maternal substance dependency before delivery.",
                    "correct_choice": "Maternal substance use treatment programs",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Maternal substance use treatment programs"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Skin-to-skin care post-delivery"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Delayed umbilical cord clamping"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Frequent breastfeeding sessions"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What reduces the likelihood of NAS at birth?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which strategy prevents Neonatal Abstinence Syndrome prenatally?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "0EB80BB2-DBF9-4055-A383-91D717E9DAE9",
                    "stem": "What is a key strategy to prevent Neonatal Abstinence Syndrome?",
                    "explanation": "The correct answer is 'Maternal substance use treatment programs,' which address the root cause of Neonatal Abstinence Syndrome by reducing maternal substance use during pregnancy.",
                    "correct_choice": "Maternal substance use treatment programs",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Maternal substance use treatment programs"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Newborn swaddling techniques"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Immediate neonatal pharmacologic treatment"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Routine prenatal ultrasound screenings"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which intervention prevents Neonatal Abstinence Syndrome most effectively?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "How can Neonatal Abstinence Syndrome be reduced prenatally?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                },
                {
                    "question_id": "A7BB7833-E0CF-4C64-8D3D-D5F97BE5FB58",
                    "stem": "How can Neonatal Abstinence Syndrome be prevented effectively?",
                    "explanation": "The correct answer is 'Maternal substance use treatment programs,' which are proven to reduce the incidence of NAS by addressing maternal substance use during pregnancy.",
                    "correct_choice": "Maternal substance use treatment programs",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Maternal substance use treatment programs"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Increased prenatal vitamin supplementation"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Frequent fetal heart rate monitoring"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Postnatal pharmacologic therapy for the newborn"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which measure helps prevent Neonatal Abstinence Syndrome?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What is an effective method to prevent NAS?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_0",
                            "excerpt": "INTRODUCTION Neonatal Abstinence Syndrome (NAS) refers to the spectrum of withdrawal symptoms experienced by newborns due to abrupt discontinuation of chronic in-utero exposure to certain substances. It most commonly occurs with opioid exposure and in that context is also termed Neonatal Opioid Withdrawal Syndrome (NOWS). However, withdrawal signs can also be seen with other central nervous [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "D20E6010-180A-4A52-8601-0D9CB98ACA0B",
            "subtopic_title": "Ethical considerations in managing NAS cases",
            "sequence_no": 18,
            "concept": "Neonatal Abstinence Syndrome (NAS) presents a unique ethical challenge in pediatric care, requiring a balance between evidence-based management and individualized, culturally sensitive approaches. International guidelines, such as those from the American Academy of Pediatrics (AAP), emphasize nonjudgmental care, pharmacological intervention when necessary, and the importance of promoting maternal-infant bonding. However, applying these guidelines in diverse contexts like India can be complex due to differences in healthcare infrastructure, societal attitudes, and legal frameworks surrounding substance use. Ethical considerations extend beyond the newborn to include maternal counseling and support, recognizing that effective NAS management often hinges on addressing maternal substance use and fostering a supportive environment for recovery. This requires collaboration across pediatrics, psychiatry, obstetrics, and social services. A common pitfall in managing NAS cases is the stigmatization of mothers, which can hinder open communication and access to care. Viewing the mother solely as a source of harm rather than a partner in the infant's recovery risks alienating her and exacerbating the cycle of substance use. Ethical care demands a compassionate approach that integrates medical treatment for the newborn with psychosocial support for the mother, while respecting cultural sensitivities and legal considerations. Pediatricians must remain vigilant in advocating for both the infant’s well-being and the mother’s rehabilitation, ensuring care is equitable and non-discriminatory.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                    "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                },
                {
                    "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                    "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                    "excerpt": "INTRODUCTION Neonatal surgical emergencies like congenital diaphragmatic hernia (CDH) and Intestinal Atresia are life-threatening conditions that require a coordinated approach between pediatricians and pediatric surgeons. Early recognition, appropriate stabilization, and timely surgical intervention are critical for survival. Both conditions can often be detected before birth, allowing for [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                    "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "C05DDC3F-56EF-40F2-B150-64BDB2BB8338",
                    "stem": "What ethical challenge arises when balancing infant care and parental rights in NAS cases?",
                    "explanation": "The ethical challenge of 'Ensuring justice for both parties' involves balancing the infant's health needs with respect for parental rights.",
                    "correct_choice": "Ensuring justice for both parties",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Ignoring parental substance use"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Overlooking infant health needs"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Ensuring justice for both parties"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Prioritizing provider convenience"
                        }
                    ],
                    "correct_choice_index": 2,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which ethical issue involves balancing care and rights in NAS?",
                            "correct_choice_index": 2
                        },
                        {
                            "variant_no": 2,
                            "stem": "In NAS management, how is justice for both parties ensured?",
                            "correct_choice_index": 2
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                            "excerpt": "INTRODUCTION Neonatal surgical emergencies like congenital diaphragmatic hernia (CDH) and Intestinal Atresia are life-threatening conditions that require a coordinated approach between pediatricians and pediatric surgeons. Early recognition, appropriate stabilization, and timely surgical intervention are critical for survival. Both conditions can often be detected before birth, allowing for [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "8CD0A971-09A0-40FA-8D2C-6F7C8D9E03BA",
                    "stem": "How should healthcare teams ethically address parental involvement in NAS treatment?",
                    "explanation": "Ethically, 'Encourage parental participation' supports family-centered care and strengthens the infant's recovery process.",
                    "correct_choice": "Encourage parental participation",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Exclude parents from decision-making"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Encourage parental participation"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Focus solely on infant care"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Prioritize legal consequences"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What ethical approach involves parents in NAS management?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "In NAS cases, how should parents be ethically included?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                            "excerpt": "INTRODUCTION Neonatal surgical emergencies like congenital diaphragmatic hernia (CDH) and Intestinal Atresia are life-threatening conditions that require a coordinated approach between pediatricians and pediatric surgeons. Early recognition, appropriate stabilization, and timely surgical intervention are critical for survival. Both conditions can often be detected before birth, allowing for [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                },
                {
                    "question_id": "5A23B5F5-7D3F-4E45-A544-D7F678E75398",
                    "stem": "What is a key ethical principle in managing Neonatal Abstinence Syndrome (NAS)?",
                    "explanation": "The principle of 'Non-maleficence towards the infant' emphasizes avoiding harm and prioritizing the newborn's well-being during NAS management.",
                    "correct_choice": "Non-maleficence towards the infant",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Autonomy of the newborn"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Non-maleficence towards the infant"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Justice for parental rights"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Beneficence for healthcare providers"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which ethical principle prioritizes harm avoidance in NAS care?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "In NAS cases, which principle ensures the infant's safety?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_5",
                            "excerpt": "INTERNATIONAL GUIDELINES VS INDIAN CONTEXT IN MANAGEMENT The American Academy of Pediatrics (AAP) and other international bodies like t he Canadian Paediatric Society and UK’s NICE have published guidelines or statements on NAS. Core recommendations across these guidelines include: prioritize non-pharmacological care, use scoring systems or evaluations to guide treatment, initiate morphine [...]"
                        },
                        {
                            "source_id": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                            "citation_link": "2_10_Neonatology_Neonatal_Surgery_congenital_diaphragmatic_hernia_intestinal_atresia_1_0",
                            "excerpt": "INTRODUCTION Neonatal surgical emergencies like congenital diaphragmatic hernia (CDH) and Intestinal Atresia are life-threatening conditions that require a coordinated approach between pediatricians and pediatric surgeons. Early recognition, appropriate stabilization, and timely surgical intervention are critical for survival. Both conditions can often be detected before birth, allowing for [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_7",
                            "excerpt": "MATERNAL COUNSELING, SOCIAL & LEGAL CONSIDERATIONS Managing NAS effectively also means managing and supporting the mother (or primary caregiver), since the infant’s well-being is intimately tied to the caregiver’s well-being. This involves counseling on substance use treatment, ensuring a safe environment, understanding legal obligations, and providing compassionate support without stigma. [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "92050023-BFCA-4C42-AD31-EF131136E91E",
            "subtopic_title": "Research and emerging therapies for NAS management",
            "sequence_no": 19,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a multifaceted condition resulting from in utero exposure to substances, most commonly opioids, and is characterized by symptoms such as central nervous system hyperirritability, autonomic dysregulation, and gastrointestinal disturbances. Effective management of NAS begins with non-pharmacological strategies, which are considered first-line care. These include creating a soothing environment with minimal sensory stimulation, promoting skin-to-skin contact, breastfeeding when appropriate, and encouraging rooming-in to foster maternal-infant bonding. Despite these measures, 50–80% of opioid-exposed infants may still require pharmacological intervention. Morphine and methadone remain the most commonly used medications, with buprenorphine emerging as a potential alternative in recent studies. The goal of pharmacotherapy is to alleviate withdrawal symptoms while minimizing the duration of treatment and hospital stay. Research into adjunctive therapies, such as the use of clonidine or phenobarbital, and innovative approaches like precision medicine, is ongoing. \n\nA critical pitfall in NAS management is over-reliance on pharmacological treatment without fully optimizing supportive care. This can inadvertently prolong hospital stays and expose infants to unnecessary medication risks. Clinicians must ensure that non-pharmacological measures are robustly implemented before initiating drug therapy. Moreover, the variability in NAS scoring tools and subjective assessments can lead to inconsistent treatment thresholds. Standardized protocols and multidisciplinary collaboration, integrating pediatrics, obstetrics, and psychiatry, are essential to delivering holistic care. As NAS continues to pose challenges at the intersection of medicine and public health, emerging therapies and evidence-based refinements in care offer hope for improving outcomes for these vulnerable infants.",
            "references": [
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                    "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                    "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                    "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                    "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                    "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "09A5EB78-C587-455F-8992-13841BABD38C",
                    "stem": "Which therapy is being studied for NAS pain relief?",
                    "explanation": "Massage therapy is being studied for NAS pain relief, showing potential benefits in calming infants and improving sleep.",
                    "correct_choice": "Massage therapy",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Massage therapy"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Laser therapy"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Cryotherapy"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Gene editing"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What therapy helps alleviate NAS discomfort?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which intervention is explored for NAS soothing?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                        }
                    ]
                },
                {
                    "question_id": "27A6FED1-E506-4F35-AFFE-434359F31CCA",
                    "stem": "What is a key feature of research on NAS management?",
                    "explanation": "Non-pharmacologic interventions, such as rooming-in and swaddling, are key features of research on NAS management.",
                    "correct_choice": "Non-pharmacologic interventions",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Non-pharmacologic interventions"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Surgical techniques"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Radiologic advancements"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Antiviral therapies"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which approach is central to NAS studies?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "What focus is prominent in NAS research?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                        }
                    ]
                },
                {
                    "question_id": "5B02AC88-D8F3-4842-AFBB-FB472D757C76",
                    "stem": "Which emerging therapy shows promise in managing NAS symptoms?",
                    "explanation": "Music therapy has shown promise in managing NAS symptoms by reducing agitation and improving feeding patterns.",
                    "correct_choice": "Music therapy",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Acupuncture"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Music therapy"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Gene therapy"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Hyperbaric oxygen"
                        }
                    ],
                    "correct_choice_index": 1,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What innovative approach aids in soothing NAS infants?",
                            "correct_choice_index": 1
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which therapy reduces agitation in NAS management?",
                            "correct_choice_index": 1
                        }
                    ],
                    "references": [
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_3",
                            "excerpt": "NON-PHARMACOLOGICAL MANAGEMENT Supportive Care as First-line: The first-line management for NAS is optimizing the infant’s environment and care to reduce symptom severity. Non-pharmacological interventions should begin at birth (or as soon as NAS is identified) and continue throughout the hospitalization. Core strategies include: creating a low-stimulation environment – dim lighting, [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_1",
                            "excerpt": "CLINICAL PRESENTATION AND DIAGNOSIS Newborns with NAS (particularly opioid-related) typically exhibit central nervous system hyperirritability, autonomic over-activity, and gastrointestinal disturbances. Common signs include: tremors, jitteriness, irritability with a high-pitched cry, increased muscle tone (hypertonia), sleep 1 disturbances, yawning and sneezing bouts, fever or temperature [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_4",
                            "excerpt": "PHARMACOLOGICAL MANAGEMENT Approximately 50–80% of infants with opioid-induced NAS will ultimately require medication despite optimal supportive care, especially if maternal opioid doses were high or long-acting. The goal of pharmacotherapy is to relieve moderate-to-severe withdrawal symptoms and allow the infant to sleep, feed, and grow. It is not to fully eliminate every sign of withdrawal [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "citation_link": "2_4_Neonatology_Neonatal_Sepsis_0_Infections_11",
                            "excerpt": "CONCLUSION Neonatal sepsis is a complex clinical condition that demands prompt recognition and management, integrating both evidence-based protocols and thoughtful adaptation to the local context. In India, the challenge is heightened by a high burden of disease and the prevalence of unusual pathogen patterns and antimicrobial resistance. Early-onset sepsis in Indian neonates is most often [...]"
                        }
                    ]
                }
            ]
        },
        {
            "subtopic_id": "0AA81491-0558-4EC0-AAC7-AFF79C8E7248",
            "subtopic_title": "Public health implications and advocacy for NAS prevention.",
            "sequence_no": 20,
            "concept": "Neonatal Abstinence Syndrome (NAS) is a pressing public health issue with significant implications for maternal and child health. This condition, caused by in-utero exposure to substances such as opioids, underscores the intersection of pediatrics, obstetrics, psychiatry, and public health. Prevention efforts must focus on a multi-tiered approach, beginning with primary prevention through public education, substance use disorder treatment programs for women of childbearing age, and access to contraception to prevent unintended pregnancies. Secondary prevention entails early identification of substance use during pregnancy through routine screening, counseling, and referral to treatment programs. Tertiary prevention involves minimizing the impact of NAS in affected neonates by ensuring timely diagnosis, supportive care, and the use of pharmacologic interventions when necessary. Advocacy for NAS prevention is critical, requiring collaboration across healthcare, social services, and policy-making sectors to address the root causes of substance use disorders and improve access to prenatal care.\n\nOne common pitfall in NAS prevention is the stigmatization of pregnant individuals with substance use disorders, which can deter them from seeking prenatal care and treatment. Healthcare providers must adopt a nonjudgmental, empathetic approach to build trust and encourage engagement with services. Additionally, public health initiatives should aim to reduce systemic barriers, such as lack of insurance coverage or treatment facilities, that hinder access to care. By addressing these challenges, healthcare professionals can play a pivotal role in reducing the burden of NAS and improving outcomes for both mothers and their infants.",
            "references": [
                {
                    "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                    "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                    "excerpt": "AND HYGIENE Health education and counseling are essential components of preventing typhoid fever. Teaching individuals about the importance of handwashing with soap and water, especially after using the toilet and before handling food, can significantly reduce the risk of transmission. Public health campaigns should emphasize proper food handling, such as washing fruits and vegetables, [...]"
                },
                {
                    "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                    "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                    "excerpt": "EPIDEMIOLOGY-GLOBAL AND INDIAN BURDEN Typhoid fever is endemic in many low- and middle-income countries, with the highest burden seen in South Asia and sub-Saharan Africa. Recent global estimates suggest about 9 million cases of typhoid fever occur worldwide each year, with approximately 110,000 deaths reported in 2019. Previous analyses have estimated higher global incidence, with figures [...]"
                },
                {
                    "source_id": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                    "citation_link": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                    "excerpt": "MEASURES After the acute illness, a subset of patients continue to harbor Salmonella Typhi in their system – a condition known as the carrier state. Pathophysiology: S. Typhi is unique in its ability to persist in the human gallbladder and biliary tree, often forming biofilms on gallstones and evading immune clearance. These asymptomatic carriers shed bacteria intermittently in stool and [...]"
                },
                {
                    "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                    "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                },
                {
                    "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                    "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                    "excerpt": "PREVENTION-LEVELS OF PREVENTION-SECONDARY PREVENTION Secondary prevention involves early diagnosis and treatment of typhoid fever to prevent complications and transmission. Prompt identification of symptoms, such as prolonged fever and abdominal discomfort, and early use of antibiotics significantly reduce the severity of the disease and prevent complications such as intestinal perforation. [...]"
                }
            ],
            "questions": [
                {
                    "question_id": "0E3FAB1A-7558-4518-AEC6-AB9AD14BBACB",
                    "stem": "Which advocacy effort best supports NAS prevention?",
                    "explanation": "Promoting substance use treatment programs best supports NAS prevention by addressing maternal addiction and reducing fetal exposure.",
                    "correct_choice": "Promoting substance use treatment programs",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Promoting substance use treatment programs"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Increasing elective cesarean deliveries"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Encouraging early weaning of infants"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Reducing routine prenatal screenings"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What advocacy measure aids in preventing NAS?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which public health effort reduces NAS cases?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                            "excerpt": "AND HYGIENE Health education and counseling are essential components of preventing typhoid fever. Teaching individuals about the importance of handwashing with soap and water, especially after using the toilet and before handling food, can significantly reduce the risk of transmission. Public health campaigns should emphasize proper food handling, such as washing fruits and vegetables, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                            "excerpt": "EPIDEMIOLOGY-GLOBAL AND INDIAN BURDEN Typhoid fever is endemic in many low- and middle-income countries, with the highest burden seen in South Asia and sub-Saharan Africa. Recent global estimates suggest about 9 million cases of typhoid fever occur worldwide each year, with approximately 110,000 deaths reported in 2019. Previous analyses have estimated higher global incidence, with figures [...]"
                        },
                        {
                            "source_id": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                            "citation_link": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                            "excerpt": "MEASURES After the acute illness, a subset of patients continue to harbor Salmonella Typhi in their system – a condition known as the carrier state. Pathophysiology: S. Typhi is unique in its ability to persist in the human gallbladder and biliary tree, often forming biofilms on gallstones and evading immune clearance. These asymptomatic carriers shed bacteria intermittently in stool and [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                            "excerpt": "PREVENTION-LEVELS OF PREVENTION-SECONDARY PREVENTION Secondary prevention involves early diagnosis and treatment of typhoid fever to prevent complications and transmission. Prompt identification of symptoms, such as prolonged fever and abdominal discomfort, and early use of antibiotics significantly reduce the severity of the disease and prevent complications such as intestinal perforation. [...]"
                        }
                    ]
                },
                {
                    "question_id": "7DFCEFF4-AFE9-4238-B96B-C2992716F1E0",
                    "stem": "What is a key public health strategy to prevent Neonatal Abstinence Syndrome (NAS)?",
                    "explanation": "Expanding access to prenatal care is a key strategy to prevent Neonatal Abstinence Syndrome (NAS) by addressing maternal substance use early.",
                    "correct_choice": "Expand access to prenatal care",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Expand access to prenatal care"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Increase neonatal intensive care units"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Promote formula feeding in hospitals"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Discourage maternal exercise during pregnancy"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "Which intervention is critical for NAS prevention?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "How can public health reduce NAS rates?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                            "excerpt": "AND HYGIENE Health education and counseling are essential components of preventing typhoid fever. Teaching individuals about the importance of handwashing with soap and water, especially after using the toilet and before handling food, can significantly reduce the risk of transmission. Public health campaigns should emphasize proper food handling, such as washing fruits and vegetables, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                            "excerpt": "EPIDEMIOLOGY-GLOBAL AND INDIAN BURDEN Typhoid fever is endemic in many low- and middle-income countries, with the highest burden seen in South Asia and sub-Saharan Africa. Recent global estimates suggest about 9 million cases of typhoid fever occur worldwide each year, with approximately 110,000 deaths reported in 2019. Previous analyses have estimated higher global incidence, with figures [...]"
                        },
                        {
                            "source_id": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                            "citation_link": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                            "excerpt": "MEASURES After the acute illness, a subset of patients continue to harbor Salmonella Typhi in their system – a condition known as the carrier state. Pathophysiology: S. Typhi is unique in its ability to persist in the human gallbladder and biliary tree, often forming biofilms on gallstones and evading immune clearance. These asymptomatic carriers shed bacteria intermittently in stool and [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                            "excerpt": "PREVENTION-LEVELS OF PREVENTION-SECONDARY PREVENTION Secondary prevention involves early diagnosis and treatment of typhoid fever to prevent complications and transmission. Prompt identification of symptoms, such as prolonged fever and abdominal discomfort, and early use of antibiotics significantly reduce the severity of the disease and prevent complications such as intestinal perforation. [...]"
                        }
                    ]
                },
                {
                    "question_id": "B36E0C84-2638-4416-98EB-CCCD7F694A08",
                    "stem": "What is an essential focus of NAS prevention campaigns?",
                    "explanation": "Maternal substance use education is an essential focus of NAS prevention campaigns to reduce risk factors during pregnancy.",
                    "correct_choice": "Maternal substance use education",
                    "choices": [
                        {
                            "choice_index": 0,
                            "choice_text": "Maternal substance use education"
                        },
                        {
                            "choice_index": 1,
                            "choice_text": "Neonatal sleep training programs"
                        },
                        {
                            "choice_index": 2,
                            "choice_text": "Routine infant vaccination schedules"
                        },
                        {
                            "choice_index": 3,
                            "choice_text": "Encouraging home births for mothers"
                        }
                    ],
                    "correct_choice_index": 0,
                    "variants": [
                        {
                            "variant_no": 1,
                            "stem": "What should NAS prevention campaigns prioritize?",
                            "correct_choice_index": 0
                        },
                        {
                            "variant_no": 2,
                            "stem": "Which focus is vital in NAS prevention efforts?",
                            "correct_choice_index": 0
                        }
                    ],
                    "references": [
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_5",
                            "excerpt": "AND HYGIENE Health education and counseling are essential components of preventing typhoid fever. Teaching individuals about the importance of handwashing with soap and water, especially after using the toilet and before handling food, can significantly reduce the risk of transmission. Public health campaigns should emphasize proper food handling, such as washing fruits and vegetables, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_DEFINITION_AND_EPIDEMIOLOGY_2",
                            "excerpt": "EPIDEMIOLOGY-GLOBAL AND INDIAN BURDEN Typhoid fever is endemic in many low- and middle-income countries, with the highest burden seen in South Asia and sub-Saharan Africa. Recent global estimates suggest about 9 million cases of typhoid fever occur worldwide each year, with approximately 110,000 deaths reported in 2019. Previous analyses have estimated higher global incidence, with figures [...]"
                        },
                        {
                            "source_id": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                            "citation_link": "Complications_and_Long_Term_Sequelae_of_Paediatric_Typhoid_Fever1_1",
                            "excerpt": "MEASURES After the acute illness, a subset of patients continue to harbor Salmonella Typhi in their system – a condition known as the carrier state. Pathophysiology: S. Typhi is unique in its ability to persist in the human gallbladder and biliary tree, often forming biofilms on gallstones and evading immune clearance. These asymptomatic carriers shed bacteria intermittently in stool and [...]"
                        },
                        {
                            "source_id": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "citation_link": "2_9_Neonatology_Neonatal_Abstinence_Syndrome_if_relevant_8",
                            "excerpt": "CONCLUSION Neonatal Abstinence Syndrome is a challenging clinical condition at the intersection of pediatrics, obstetrics, psychiatry, and public health. It primarily manifests as opioid withdrawal in newborns but can involve multiple substances. A standard clinical approach includes early recognition, aided by tools like the Finnegan scoring system or the newer Eat-Sleep-Console framework, [...]"
                        },
                        {
                            "source_id": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                            "citation_link": "TYPHOID_ENTERIC_FEVER_PREVENTION_1",
                            "excerpt": "PREVENTION-LEVELS OF PREVENTION-SECONDARY PREVENTION Secondary prevention involves early diagnosis and treatment of typhoid fever to prevent complications and transmission. Prompt identification of symptoms, such as prolonged fever and abdominal discomfort, and early use of antibiotics significantly reduce the severity of the disease and prevent complications such as intestinal perforation. [...]"
                        }
                    ]
                }
            ]
        }
    ]
}